BOEHRINGER-INGELHEIM
10.5.2023 09:33:26 CEST | Business Wire | Press release
Boehringer Ingelheim and Zealand Pharma A/S (Nasdaq: ZEAL) today announced that patients treated with BI 456906 achieved up to 14.9% weight loss after 46 weeks, using the planned maintenance dose. The phase II clinical trial evaluating the effect of different doses of the novel glucagon/GLP-1 receptor dual agonist BI 456906 in people living with obesity or overweight without type 2 diabetes (NCT04667377) met its primary endpoint. These results including an analysis of the actual maintenance dose indicating even greater weight loss will be presented at the 2023 American Diabetes Association’s 83rd Scientific Sessions in San Diego, CA, U.S. Until then, the data is under embargo.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230510005447/en/
“Obesity is one of many cardio-renal-metabolic diseases, which together represent one of the fastest growing health challenges worldwide. The distinct mode of action of BI 456906 targets multiple pathways pivotal to metabolic regulation, including those associated with obesity and liver diseases,” said Carinne Brouillon, Head of Human Pharma, Boehringer Ingelheim. “With our longstanding heritage in cardio-renal-metabolic diseases, we are excited by the findings and potential implications for millions of people who urgently need healthcare solutions.”
“We are both enthusiastic about these data and encouraged by the clinical outcomes announced today,” said David Kendall, M.D., Chief Medical Officer, Zealand Pharma. “At Zealand Pharma we continue our long-term commitment to the discovery and development of novel differentiated peptide therapeutics that target critical metabolic pathways to achieve substantial weight loss while addressing the complex pathophysiology of overweight and obesity.”
In 2016, more than 1 billion people worldwide were living with cardio-renal-metabolic (CRM) diseases such as obesity, type 2 diabetes, chronic kidney disease, liver disease, heart failure and cardiovascular disease1-10. Obesity is a major global health challenge, and the worldwide prevalence has more than doubled over the past four decades11. The World Obesity Federation predicts that by 2025, 2.7 billion adults could be living with obesity or overweight, placing a high burden on individuals, healthcare systems and society11.
Notes to editors
Please click on the following link for ‘Notes to editors’ and ‘References’
https://www.boehringer-ingelheim.com/phase-ll-trial-results-in-obesity-or-overweight
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230510005447/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Corient Expands to Cayman Islands with Acquisition of FortCay Family Office Advisory23.9.2026 15:00:00 CEST | Press release
Establishes Corient’s presence in a premier global wealth jurisdiction and enhances its expertise in serving families with complex cross-border needs Corient, the world’s largest multi-family office and non-bank wealth manager focused on ultra-high-net-worth and high-net-worth clients, today announced the addition of FortCay Family Advisory (“FortCay”), a Cayman Islands wealth manager and multi-family office. FortCay, founded by Billy Harty and Matt Houghton, serves 14 ultra-high-net-worth families representing approximately US$2.6 billion in client assets, providing comprehensive wealth management, estate planning and family office services. The acquisition establishes Corient in the Cayman Islands, a leading international financial center and important hub for private wealth, extending the firm’s reach in a strategically important market. “A meaningful share of the world’s most complex family wealth is structured and administered in the Cayman Islands,” said Kurt MacAlpine, Founding
GTN and Solidus Labs Announce Landmark Surveillance Partnership23.9.2026 15:00:00 CEST | Press release
GTN, the global fintech, and Solidus Labs, the category-definer in multidimensional market integrity, today announced a landmark partnership that deploys Solidus Labs' HALO platform across GTN's operations. Under the partnership, HALO is deployed across GTN's global order book, delivering integrated trade surveillance and transaction monitoring across equities, fixed income, derivatives, FX and digital/crypto assets. This means for brokers, banks, asset managers and fintechs, the era of surveillance as a barrier to market participation is over. Beyond GTN's internal compliance operations, this partnership introduces a surveillance layer that lets GTN's 500+ clients access dedicated HALO tenants through GTN's infrastructure. This embeds institutional-grade surveillance capabilities into the infrastructure that those firms already run their business on. Rather than each client independently procuring, integrating and running a surveillance stack, GTN's model lets firms across its institu
SS&C Technologies Unveils Portfolio of AI-Enabled Enhancements; Debuts Six-Part Agentic Blueprint Docuseries at SS&C Deliver23.9.2026 15:00:00 CEST | Press release
New AI-enabled solutions and enhancements roll out across SS&C’s financial services and healthcare businesses, alongside a six-part docuseries on the company’s own agentic AI transformation SS&C Technologies Holdings, Inc. (Nasdaq: SSNC) today unveiled a suite of next-generation solutions at its annual SS&C Deliver 2026 conference. More than 1,100 leaders from the financial services and healthcare industries gathered in Orlando, Florida, to learn how SS&C is optimizing business workflows with AI-enabled services. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260923521682/en/ A core technology set spanning wealth, retirement, alternatives and asset management is built on the SS&C AI Gateway governance platform. SS&C WorkHQ, the company’s award-winning agentic orchestration platform, enables interoperability across these solutions. SS&C also debuted the six-part The Blueprint: Customer Zero docuseries, a behind-the-scenes loo
Principal Asset Management® and Longevity Partners Launch REsponsible Asset Solutions to Scale Real Estate Decarbonization Strategies23.9.2026 15:00:00 CEST | Press release
New platform combines institutional investment expertise with technical delivery capabilities to help real estate owners implement decarbonization strategies that enhance asset value, reduce operating costs and support long-term performance. Principal Asset Management® and Longevity Partners today announced the launch of REsponsible Asset Solutions (RAS), a new platform designed to help institutional real estate owners identify, underwrite, and execute decarbonization initiatives that improve building performance, reduce energy consumption and enhance long-term asset value while meeting investment return objectives. REsponsible Asset Solutions brings together the institutional investment expertise of Principal Asset Management's dedicated real estate platform, a top-10 global real estate manager1 with $108 billion in assets under management2 and more than 65 years of experience, and Longevity Partners' engineering, procurement, and implementation capabilities. By combining deep real es
The Estée Lauder Companies and the Breast Cancer Research Foundation Launch Largest Global Research Initiative on Breast Cancer in Younger Women23.9.2026 14:30:00 CEST | Press release
$15 million grant from The Estée Lauder Companies Charitable Foundation establishes the Global Research Initiative on Breast Cancer in Younger Women, a landmark multi-year effort uniting scientists worldwide to address one of the most underfunded areas of breast cancer research. The Estée Lauder Companies today announced a new five-year commitment to the Breast Cancer Research Foundation to establish the Global Research Initiative on Breast Cancer in Younger Women. This first-of-its-kind research coalition will address the alarming global rise in breast cancer diagnoses among younger women, building on more than three decades of partnership between The Estée Lauder Companies and the Breast Cancer Research Foundation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260923337773/en/ The $15 millioncommitment from The Estée Lauder Companies Charitable Foundation is designed to confront an urgent and significantly underfunded nee
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom